Hamoon Eshraghi1, Dimosthenis Mantopoulos1, Leejee H Suh2, Francisco Zaldana3, Howard F Fine1. 1. Department of Ophthalmology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. 2. Department of Ophthalmology, Columbia University College of Physicians and Surgeons, New York, New York, USA. 3. Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Abstract
BACKGROUND: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATION: Case report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONS: The systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.
BACKGROUND: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATION: Case report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurred vision after systemic treatment with the investigational EGFR inhibitor ABT-414. The patient had best corrected visual acuity of 20/60 right eye and 20/50 left eye. Ophthalmic examination revealed corneal toxicity with whorl-like opacities in the inferior interpalpebral cornea. The patient was treated with topical fluoromethalone and lifitegrast, and his ocular symptoms as well as the corneal findings improved. CONCLUSIONS: The systemic use of EGFR inhibitor ABT-414 may be associated with corneal toxicity and the effects are reversible with treatment.
Authors: Andrew C Phillips; Erwin R Boghaert; Kedar S Vaidya; Michael J Mitten; Suzanne Norvell; Hugh D Falls; Peter J DeVries; Dong Cheng; Jonathan A Meulbroek; Fritz G Buchanan; Laura M McKay; Neal C Goodwin; Edward B Reilly Journal: Mol Cancer Ther Date: 2016-02-04 Impact factor: 6.261
Authors: David A Reardon; Andrew B Lassman; Martin van den Bent; Priya Kumthekar; Ryan Merrell; Andrew M Scott; Lisa Fichtel; Erik P Sulman; Erica Gomez; JuDee Fischer; Ho-Jin Lee; Wijith Munasinghe; Hao Xiong; Helen Mandich; Lisa Roberts-Rapp; Peter Ansell; Kyle D Holen; Hui K Gan Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300